0001356090 false 0001356090 2021-05-24 2021-05-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares




Washington, D.C. 20549





Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): May 24, 2021



(Exact name of registrant as specified in its charter)

Virginia   001-36042   26-0084895

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer

Identification No.)


20374 Seneca Meadows Parkway, Germantown, Maryland 20876

(Address of principal executive offices) (Zip Code)


(301) 556-9900

(Registrant’s telephone number, including area code)



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to 12(b) of the Act:

Title of each class  




Name of each exchange

on which registered

Common Stock, No Par Value   PGEN   Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 5.02Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers


As previously announced, Precigen, Inc. (the “Company”) is currently conducting an executive search process to identify a new Chief Financial Officer with the qualifications to contribute to the Company’s growth from a clinical stage company to a commercial organization. On May 24, 2021, the Company accepted D. Bradford Osborne’s resignation from his position of Vice President, Finance and Accounting and interim principal accounting officer to pursue a new opportunity. Mr. Osborne and the Company have agreed that the resignation will be effective June 10, 2021.


Effective June 10, 2021, the Company will appoint James V. Lambert (age 56), currently the Executive Director, Finance for PGEN Therapeutics, Inc., a wholly owned subsidiary of the Company (“PGEN Therapeutics”), to serve as principal accounting officer for an interim period while the Company continues its search for a new Chief Financial Officer. Mr. Lambert joined PGEN Therapeutics in June 2017 in connection with the acquisition of GenVec, Inc. and has since served in the role of Executive Director, Finance. From 2014 to 2017 Mr. Lambert served in the positions of GenVec’s Senior Director and then Vice President, Accounting and Finance, Corporate Controller and Treasurer. During this period Mr. Lambert also served as GenVec’s principal financial officer and principal accounting officer. There are no arrangements or understandings between Mr. Lambert and any other persons pursuant to which he was selected as an officer of the Company, and Mr. Lambert is not related to any other executive officer or director of the Company. Mr. Lambert has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There will not be any changes to Mr. Lambert’s compensation arrangements in connection with his interim appointment.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Precigen, Inc.  
  By:   /s/ Donald P. Lehr   
      Donald P. Lehr  
      Chief Legal Officer  


Dated: May 27, 2021